|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
PT2768942T
(pt)
|
2011-10-17 |
2020-01-21 |
Massachusetts Inst Technology |
Entrega intracelular
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
KR102243597B1
(ko)
|
2013-08-16 |
2021-04-26 |
메사추세츠 인스티튜트 오브 테크놀로지 |
세포로의 선택적 물질 전달
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
US20170335331A1
(en)
*
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
|
KR20170074235A
(ko)
|
2014-10-31 |
2017-06-29 |
메사추세츠 인스티튜트 오브 테크놀로지 |
면역 세포로의 생체분자의 전달
|
|
CN107002089B
(zh)
|
2014-11-14 |
2021-09-07 |
麻省理工学院 |
化合物和组合物向细胞中的破坏和场实现的递送
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
US12359197B2
(en)
|
2014-12-12 |
2025-07-15 |
Etagen Pharma, Inc. |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
CN107250373A
(zh)
|
2015-01-12 |
2017-10-13 |
麻省理工学院 |
通过微流体递送实现的基因编辑
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3274454B1
(en)
*
|
2015-03-25 |
2021-08-25 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
AU2016243583B2
(en)
*
|
2015-03-27 |
2022-03-10 |
President And Fellows Of Harvard College |
Modified T cells and methods of making and using the same
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
CA2986310A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
WO2016183236A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
CN108026526B
(zh)
|
2015-06-09 |
2023-05-12 |
爱迪塔斯医药公司 |
用于改善移植的crispr/cas相关方法和组合物
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
AU2016289530B2
(en)
|
2015-07-09 |
2021-05-06 |
Massachusetts Institute Of Technology |
Delivery of materials to anucleate cells
|
|
HK1255161A1
(zh)
|
2015-07-15 |
2019-08-09 |
Juno Therapeutics, Inc. |
用於过继性细胞治疗的工程细胞
|
|
US10906951B2
(en)
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
JP6974681B2
(ja)
|
2015-07-29 |
2021-12-01 |
オーエヌケー セラピューティクス リミテッド |
細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
|
|
GB2592821B
(en)
*
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
CN115491373A
(zh)
*
|
2015-10-30 |
2022-12-20 |
爱迪塔斯医药公司 |
治疗单纯疱疹病毒的crispr/cas相关方法及组合物
|
|
KR102787119B1
(ko)
|
2015-11-30 |
2025-03-27 |
듀크 유니버시티 |
유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
|
|
WO2017093969A1
(en)
*
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
JP7033535B2
(ja)
*
|
2016-01-12 |
2022-03-10 |
スクイーズ バイオテクノロジーズ カンパニー |
複合体の細胞内送達
|
|
WO2017147278A1
(en)
|
2016-02-25 |
2017-08-31 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology
|
|
EP3423580A1
(en)
*
|
2016-03-04 |
2019-01-09 |
Editas Medicine, Inc. |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
WO2017165412A2
(en)
*
|
2016-03-21 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
KR20180134412A
(ko)
*
|
2016-04-22 |
2018-12-18 |
인텔리아 테라퓨틱스, 인크. |
전사 인자 4에서 트라이뉴클레오타이드 반복부와 연관된 질환의 치료를 위한 조성물 및 방법
|
|
CN107304434A
(zh)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
一种免疫细胞治疗的双功能新型载体
|
|
CA3022319A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Tod M. Woolf |
Improved methods for genome editing with and without programmable nucleases
|
|
US20190136230A1
(en)
|
2016-05-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
WO2018001241A1
(zh)
|
2016-06-28 |
2018-01-04 |
北京百奥赛图基因生物技术有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
US12595478B2
(en)
|
2016-06-29 |
2026-04-07 |
The Broad Institute, Inc. |
Crispr-Cas systems having destabilization domain
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
KR102546839B1
(ko)
|
2016-08-03 |
2023-06-23 |
워싱턴 유니버시티 |
키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
WO2018031683A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
IL308824A
(en)
|
2016-08-17 |
2024-01-01 |
Factor Bioscience Inc |
Nucleic acid products and methods of administration thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
|
JP7623784B2
(ja)
|
2016-10-13 |
2025-01-29 |
ジュノー セラピューティクス インコーポレイテッド |
トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
|
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
AU2017347854B2
(en)
*
|
2016-10-27 |
2022-12-08 |
Intima Bioscience, Inc. |
Viral methods of T cell therapy
|
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
CN110121558B
(zh)
*
|
2016-11-28 |
2023-06-13 |
日商那帕洁制药股份有限公司 |
化学修饰siRNA
|
|
KR20190098747A
(ko)
|
2016-12-05 |
2019-08-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료법을 위한 조작된 세포의 제조방법
|
|
CN110191955B
(zh)
|
2016-12-13 |
2024-05-31 |
西雅图儿童医院（Dba西雅图儿童研究所） |
在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
JP2020503043A
(ja)
*
|
2016-12-30 |
2020-01-30 |
セルラリティ インコーポレイテッド |
遺伝子改変されたナチュラルキラー細胞
|
|
US20190381157A1
(en)
*
|
2017-01-29 |
2019-12-19 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
US12440578B2
(en)
|
2017-02-22 |
2025-10-14 |
Io Biosciences, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
|
US10828330B2
(en)
*
|
2017-02-22 |
2020-11-10 |
IO Bioscience, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
WO2018175636A2
(en)
*
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MA48797A
(fr)
|
2017-05-25 |
2020-04-08 |
Bluebird Bio Inc |
Variants de l'endonucléase cblb , compositions et procédés d'utilisation
|
|
MX2019014640A
(es)
|
2017-06-09 |
2020-10-05 |
Editas Medicine Inc |
Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.
|
|
WO2018232356A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
CN109963944A
(zh)
*
|
2017-06-20 |
2019-07-02 |
江苏恒瑞医药股份有限公司 |
体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA
|
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US20200140896A1
(en)
*
|
2017-06-30 |
2020-05-07 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
KR20260026092A
(ko)
|
2017-09-19 |
2026-02-25 |
메사추세츠 인스티튜트 오브 테크놀로지 |
키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
|
|
JP2020537515A
(ja)
|
2017-10-03 |
2020-12-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｈｐｖ特異的結合分子
|
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
JP7101419B2
(ja)
|
2017-10-27 |
2022-07-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
内因性ｔ細胞受容体の標的置換
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
EP3707258A1
(en)
|
2017-11-06 |
2020-09-16 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
|
US20210187018A1
(en)
*
|
2017-12-07 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Cytobiologics and therapeutic uses thereof
|
|
US11738047B2
(en)
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
|
EP3724327A4
(en)
*
|
2017-12-14 |
2022-01-12 |
EZY Biotech LLC |
SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
EP3740580A4
(en)
|
2018-01-19 |
2021-10-20 |
Duke University |
GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
|
|
WO2019178427A1
(en)
|
2018-03-14 |
2019-09-19 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
|
CN112040986A
(zh)
|
2018-03-15 |
2020-12-04 |
Ksq治疗公司 |
用于改进的免疫疗法的基因调控组合物和方法
|
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
CN112153990A
(zh)
*
|
2018-03-23 |
2020-12-29 |
纽约市哥伦比亚大学理事会 |
用于常染色体显性疾病的基因编辑
|
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
MA52207A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
|
|
AU2019252925A1
(en)
*
|
2018-04-13 |
2020-07-30 |
Sigma-Aldrich Co. Llc. |
Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
WO2019210057A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
DK3806903T5
(da)
|
2018-06-14 |
2024-08-19 |
2Seventy Bio Inc |
Cd79a kimæriske antigenreceptorer
|
|
CN108866004A
(zh)
*
|
2018-06-26 |
2018-11-23 |
奥妙生物技术（广州）有限公司 |
Shp-1敲除的t细胞及其构建方法
|
|
WO2020014235A1
(en)
|
2018-07-09 |
2020-01-16 |
The Regents Of The University Of California |
Gene targets for t-cell-based immunotherapy
|
|
CN112955174A
(zh)
|
2018-07-09 |
2021-06-11 |
旗舰先锋创新V股份有限公司 |
融合剂脂质体组合物和其用途
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
WO2020022802A1
(ko)
*
|
2018-07-25 |
2020-01-30 |
주식회사 툴젠 |
인위적인 유전자 조작을 통한 자가면역질환 치료
|
|
CN112888461A
(zh)
*
|
2018-07-26 |
2021-06-01 |
株式会社图尔金 |
抗凝因子的基因编辑
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
US20200080056A1
(en)
*
|
2018-09-06 |
2020-03-12 |
The Trustees Of The University Of Pennsylvania |
CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy
|
|
US20220053740A1
(en)
*
|
2018-09-11 |
2022-02-24 |
Board Of Regents, The University Of Texas System |
A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN113227374A
(zh)
*
|
2018-10-16 |
2021-08-06 |
因特利亚治疗公司 |
用于免疫疗法的组合物和方法
|
|
KR102929494B1
(ko)
*
|
2018-10-29 |
2026-02-20 |
차이나 어그리컬처럴 유니버시티 |
신규 CRISPR/Cas12f 효소 및 시스템
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
CN113631718A
(zh)
|
2018-11-14 |
2021-11-09 |
旗舰先锋创新V股份有限公司 |
用于特定隔室货物递送的组合物和方法
|
|
CN113544266A
(zh)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
Crispr相关转座酶系统和其使用方法
|
|
US12264323B2
(en)
|
2018-12-17 |
2025-04-01 |
The Broad Institute, Inc. |
CRISPR CPF1 direct repeat variants
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US20220096551A1
(en)
*
|
2019-01-28 |
2022-03-31 |
Bar Ilan University |
Combinations, nanoparticles and methods for controlling natural killer cell activation and function
|
|
CA3129613A1
(en)
|
2019-02-12 |
2020-08-20 |
Provincial Health Services Authority |
Compositions and methods for enhanced lymphocyte-mediated immunotherapy
|
|
WO2021226363A1
(en)
*
|
2020-05-08 |
2021-11-11 |
Metagenomi Ip Technologies, Llc |
Enzymes with ruvc domains
|
|
PE20211959A1
(es)
|
2019-02-15 |
2021-09-30 |
Editas Medicine Inc |
Celulas asesinas naturales (nk) modificadas para inmunoterapia
|
|
WO2020191233A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
CA3136119A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
WO2020223535A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
SG11202112161TA
(en)
|
2019-05-03 |
2021-12-30 |
Specific Biologics Inc |
Lipid-encapsulated dual-cleaving endonuclease for dna and gene editing
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US12188045B2
(en)
|
2019-06-07 |
2025-01-07 |
KSQ Therapeutics, Inc. |
Guide RNA combinations and methods of use
|
|
WO2020252110A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Bluebird Bio, Inc. |
Compositions and methods for treating cancer
|
|
WO2020263399A1
(en)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021022043A2
(en)
|
2019-07-30 |
2021-02-04 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP4438729A3
(en)
*
|
2019-12-09 |
2025-03-26 |
Caribou Biosciences, Inc. |
Crispr abasic restricted nucleotides and crispr accuracy via analogs
|
|
AU2020418199B2
(en)
*
|
2020-01-02 |
2024-06-13 |
Ningbo T-Maximum Biopharmaceuticals Co., Ltd. |
Modified immune effector cell and preparation method therefor
|
|
US20210254005A1
(en)
*
|
2020-01-23 |
2021-08-19 |
Kangstem Biotech Co., Ltd. |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
|
|
BR112022017924A2
(pt)
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
|
US20250263752A1
(en)
|
2020-04-21 |
2025-08-21 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021216623A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
IL297761A
(en)
|
2020-05-08 |
2022-12-01 |
Broad Inst Inc |
Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
|
|
CN115835873A
(zh)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
用于产生表达重组受体的供体分批细胞的方法
|
|
EP4162052A4
(en)
*
|
2020-06-03 |
2024-07-10 |
Mammoth Biosciences, Inc. |
PROGRAMMABLE NUCLEASES AND METHODS OF USE
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
CN114164231B
(zh)
*
|
2020-09-10 |
2024-05-17 |
上海邦耀生物科技有限公司 |
对细胞中的靶位点进行基因编辑的方法
|
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
EP4259159A4
(en)
*
|
2020-12-14 |
2025-04-09 |
Emendobio Inc. |
Biallelic knockout of trac
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
CA3207166A1
(en)
*
|
2021-02-01 |
2022-08-04 |
Angelo Leone Lombardo |
Gene silencing
|
|
US12171813B2
(en)
|
2021-02-05 |
2024-12-24 |
Christiana Care Gene Editing Institute, Inc. |
Methods of and compositions for reducing gene expression and/or activity
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
CN117321200A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
评估病毒载体颗粒效力的方法
|
|
WO2022215982A1
(ko)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Trac 유전자에 상보적인 가이드 rna 및 이의 용도
|
|
WO2022232839A1
(en)
|
2021-04-30 |
2022-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for improved production of primary cd34+ cells
|
|
EP4355879A4
(en)
|
2021-06-14 |
2025-07-23 |
Kamau Therapeutics Inc |
METHODS FOR GENETIC MODIFICATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR ERYTHROCYTE-SPECIFIC EXPRESSION OF THERAPEUTIC PROTEINS
|
|
EP4359541A4
(en)
|
2021-06-23 |
2025-04-30 |
Editas Medicine, Inc. |
Engineered cells for therapy
|
|
WO2022269393A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
|
US20240316102A1
(en)
|
2021-07-01 |
2024-09-26 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
AU2022335499A1
(en)
|
2021-08-27 |
2024-02-22 |
Metagenomi Therapeutics, Inc. |
Enzymes with ruvc domains
|
|
JP2024537991A
(ja)
|
2021-10-14 |
2024-10-18 |
アーセナル バイオサイエンシズ インコーポレイテッド |
共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
|
|
EP4426830A1
(en)
|
2021-11-01 |
2024-09-11 |
Sigma-Aldrich Co. LLC |
Electroporation enhancers for crispr-cas systems
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
KR20240126870A
(ko)
|
2021-12-22 |
2024-08-21 |
캠프4 테라퓨틱스 코포레이션 |
조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4508073A1
(en)
|
2022-04-14 |
2025-02-19 |
Board of Regents of the University of Nebraska |
Cell therapy for alzheimer's disease
|
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
JP2025525439A
(ja)
|
2022-06-30 |
2025-08-05 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
KR20250077608A
(ko)
|
2022-08-19 |
2025-05-30 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법
|
|
US20260055146A1
(en)
|
2022-08-24 |
2026-02-26 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
EP4583876A1
(en)
|
2022-09-08 |
2025-07-16 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
US20260091113A1
(en)
*
|
2022-09-19 |
2026-04-02 |
Emendobio Inc. |
Biallelic Knockout of CTLA4
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
IL322949A
(en)
|
2023-03-03 |
2025-10-01 |
Arsenal Biosciences Inc |
Systems targeting PSMA and CA9
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4716750A1
(en)
|
2023-05-23 |
2026-04-01 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
KR20260018068A
(ko)
|
2023-05-26 |
2026-02-06 |
에디타스 메디신, 인코포레이티드 |
Cd70 발현을 표적화하는 crispr 관련 방법 및 조성물
|
|
WO2024249348A2
(en)
|
2023-05-26 |
2024-12-05 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting fl1-1 expression
|
|
WO2024249342A1
(en)
|
2023-05-26 |
2024-12-05 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting ptpn2 expression
|
|
CN116539885B
(zh)
*
|
2023-07-06 |
2023-09-29 |
上海秤信生物科技有限公司 |
用于乳腺癌早期检测的肿瘤自身抗原/抗体组合及应用
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025212519A1
(en)
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
WO2025213127A1
(en)
|
2024-04-05 |
2025-10-09 |
Indapta Therapeutics, Inc. |
Treatment of autoimmune diseases or conditions with natural killer cells
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2025245399A1
(en)
|
2024-05-23 |
2025-11-27 |
Indapta Therapeutics, Inc. |
Method of treating cancer with natural killer cells
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026064475A1
(en)
|
2024-09-18 |
2026-03-26 |
Editas Medicine, Inc. |
Crispr cas-related methods and compositions targeting ptpn2 expression
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|